Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

10.6K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
10.6K
RNA Editing02:23

RNA Editing

9.0K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.0K
CRISPR01:59

CRISPR

51.6K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
51.6K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

6.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three immunoregulatory signatures define non-productive HIV infection in stem cell memory CD4<sup>+</sup> T cells.

Nature communications·2026
Same author

A transfer RNA inosine modification drives genome-wide synonymous recoding across human commensal bacterial families.

PNAS nexus·2026
Same author

Exchange-Coupled Localized States Enable Weak-Field Spin-Polarized Lasing in All-Inorganic CsPbBr<sub>3</sub> Microcrystals.

The journal of physical chemistry letters·2026
Same author

Manipulating the Carrier Transfer Dynamics Enabled by Electron Cloud Redistribution for Low-Threshold Red Perovskite Single-Mode Laser.

ACS applied materials & interfaces·2026
Same author

Three immunoregulatory signatures define non-productive HIV infection in CD4<sup>+</sup> T memory stem cells.

bioRxiv : the preprint server for biology·2026
Same author

RNA localization to nuclear speckles follows splicing logic.

Nucleic acids research·2026

Related Experiment Video

Updated: Jul 8, 2025

Rare Event Detection Using Error-corrected DNA and RNA Sequencing
10:36

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Published on: August 3, 2018

12.1K

Engineered mischarged transfer RNAs for correcting pathogenic missense mutations.

Yichen Hou1, Wen Zhang2, Philip T McGilvray3

  • 1Committee on Genomics, Genetics and Systems Biology, University of Chicago, Chicago, IL 60637, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 17, 2023
PubMed
Summary
This summary is machine-generated.

Researchers developed missense-correcting transfer RNAs (mc-tRNAs) to treat genetic diseases caused by missense mutations. This novel RNA therapy shows promise for correcting these common mutations, offering a new treatment avenue.

Keywords:
genetic disorderlimb-girdle muscular dystrophy type 2Amischargingmissense correcting tRNAmistranslationtRNA therapy

More Related Videos

CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
08:31

CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation

Published on: June 20, 2019

14.1K
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

5.5K

Related Experiment Videos

Last Updated: Jul 8, 2025

Rare Event Detection Using Error-corrected DNA and RNA Sequencing
10:36

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Published on: August 3, 2018

12.1K
CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
08:31

CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation

Published on: June 20, 2019

14.1K
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

5.5K

Area of Science:

  • Molecular Biology
  • Genetic Engineering
  • Therapeutic Development

Background:

  • Missense mutations cause ~50% of human genetic diseases, with limited treatment options.
  • Current RNA therapies target nonsense mutations, leaving missense mutations unaddressed.
  • Transfer RNA (tRNA) engineering offers a potential strategy for missense mutation correction.

Purpose of the Study:

  • To engineer missense-correcting tRNAs (mc-tRNAs) for therapeutic applications.
  • To establish a versatile pipeline for mc-tRNA development and validation.
  • To demonstrate mc-tRNA potential in treating genetic disorders caused by missense mutations.

Main Methods:

  • Developed fluorescent protein reporters to assess missense mutation correction efficiency.
  • Engineered mc-tRNAs to correct specific serine and arginine missense mutations.
  • Validated mc-tRNA function using mass spectrometry, sequencing, and transcriptomic analysis.

Main Results:

  • Successfully engineered mc-tRNAs that corrected missense mutations in reporter systems.
  • Confirmed amino acid substitutions and mc-tRNA expression, with minimal transcriptomic changes observed.
  • Demonstrated mc-tRNA efficacy in rescuing a pathogenic CAPN3 missense mutant relevant to LGMD2A.

Conclusions:

  • Established a versatile pipeline for engineering mc-tRNAs to correct missense mutations.
  • Validated mc-tRNAs as a potential therapeutic platform for genetic disorders.
  • Highlighted the therapeutic potential of mc-tRNAs for previously untreatable missense mutations.